Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 4/20 | 0.35 |
| ▸ | THRA | P10827 | 3/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842617 | 0.84 | TAAR1 (0.47) | LMNAPNMT | |
| SCHEMBL17880793 | 0.83 | CSNK2A1 (0.44) | CSNK2A1LMNAHRH3THRBTHRA | |
| SCHEMBL19658033 | 0.83 | CSNK2A1 (0.43) | CSNK2A1LMNAHRH3LOXL2ABAT | |
| SCHEMBL19365984 | 0.81 | CYP1A2 (0.43) | LMNATHRBTHRA | |
| SCHEMBL2737191 | 0.79 | GABRA1 (0.42) | LMNATHRBTHRA | |
| SCHEMBL3694809 | 0.78 | LOXL2 (0.41) | CSNK2A1HRH3LOXL2PNMT | |
| SCHEMBL3098498 | 0.78 | CSNK2A1 (0.51) | CSNK2A1LOXL2PNMT | |
| SCHEMBL10947856 | 0.78 | THRA (0.47) | LMNATHRBTHRAABATENPP2 | |
| SCHEMBL27102119 | 0.76 | ESR1 (0.41) | LMNATHRBTHRA | |
| SCHEMBL27411609 | 0.76 | LMNA (0.35) | LMNATHRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546440-B2 | Substituted bicyclic imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. | 2011-09-29 | — | — | US | disclosed |
| EP-1477186-B1 | ANTIPRURITICS | SHIONOGI & CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-7420053-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2008-09-02 | — | — | US | disclosed |
| EP-1375489-B1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1219612-B1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20070088020-A1 | 2-imino-1,3-thiazine derivatives | HANASAKI KOJI | 2007-04-19 | — | — | US | disclosed |
| CN-1301981-C | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO (JP) | 2007-02-28 | — | — | CN | disclosed |
| US-7183275-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-6916806-B2 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | HANASAKI KOJI (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6818640-B1 | BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS | SHIONOGI & CO., LTD. (JP) | 2004-11-16 | — | — | US | disclosed |
| CN-1514831-A | Medicinal composition containing 1,3-thiazine derivative | ��Ұ����ҩ��ʽ���� | 2004-07-21 | — | — | CN | disclosed |
| US-20040116326-A1 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1375489-A1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| CN-1387519-A | 2-imino-1, 3-thiazine derivatives | SHIONOGI & CO (JP) | 2002-12-25 | — | — | CN | disclosed |
| EP-1219612-A1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | CSNK2A1 515/4885LMNA 4521/4885HRH3 25/4885 |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CSNK2A1 188/4885LMNA 1002/4885HRH3 146/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CSNK2A1 892/4885LMNA 4604/4885HRH3 17/4885 |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | CNR2, CNR1, HTR2C | CSNK2A1 480/4885LMNA 3850/4885HRH3 245/4885 |
| US-20070088020-A1 | 2-imino-1,3-thiazine derivatives | CNR2, CNR1, HTR2C | CSNK2A1 480/4885LMNA 3850/4885HRH3 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.